SG Americas Securities LLC Has $300,000 Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

SG Americas Securities LLC lessened its holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) by 72.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 36,563 shares of the company’s stock after selling 97,264 shares during the quarter. SG Americas Securities LLC’s holdings in Wave Life Sciences were worth $300,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Driehaus Capital Management LLC lifted its position in Wave Life Sciences by 62.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 908,096 shares of the company’s stock worth $4,531,000 after buying an additional 348,300 shares in the last quarter. Mackenzie Financial Corp grew its stake in shares of Wave Life Sciences by 13.6% in the second quarter. Mackenzie Financial Corp now owns 15,887 shares of the company’s stock valued at $79,000 after acquiring an additional 1,905 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Wave Life Sciences by 3.6% in the second quarter. The Manufacturers Life Insurance Company now owns 139,790 shares of the company’s stock valued at $698,000 after acquiring an additional 4,914 shares in the last quarter. Millennium Management LLC grew its stake in shares of Wave Life Sciences by 1.8% in the second quarter. Millennium Management LLC now owns 1,664,300 shares of the company’s stock valued at $8,305,000 after acquiring an additional 28,690 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Wave Life Sciences by 26.3% in the second quarter. AQR Capital Management LLC now owns 33,529 shares of the company’s stock valued at $167,000 after acquiring an additional 6,973 shares in the last quarter. Institutional investors and hedge funds own 89.73% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Paul Bolno sold 48,366 shares of the stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $5.78, for a total value of $279,555.48. Following the completion of the sale, the chief executive officer now owns 359,059 shares of the company’s stock, valued at approximately $2,075,361.02. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Chris Francis sold 208,836 shares of Wave Life Sciences stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $13.67, for a total transaction of $2,854,788.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Paul Bolno sold 48,366 shares of the business’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $5.78, for a total value of $279,555.48. Following the completion of the transaction, the chief executive officer now owns 359,059 shares in the company, valued at $2,075,361.02. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 364,822 shares of company stock worth $4,645,768. 29.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

WVE has been the topic of several research reports. Wells Fargo & Company upped their price target on shares of Wave Life Sciences from $11.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday. Royal Bank of Canada increased their target price on shares of Wave Life Sciences from $5.00 to $7.00 and gave the company a “sector perform” rating in a research report on Friday, October 4th. B. Riley increased their target price on shares of Wave Life Sciences from $11.00 to $19.00 and gave the company a “buy” rating in a research report on Thursday, October 3rd. Mizuho reaffirmed an “outperform” rating and set a $19.00 price objective on shares of Wave Life Sciences in a research report on Tuesday, June 25th. Finally, JPMorgan Chase & Co. increased their target price on Wave Life Sciences from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $18.56.

Wave Life Sciences Stock Up 4.8 %

WVE stock opened at $15.31 on Friday. The business’s 50-day moving average price is $7.10 and its 200-day moving average price is $6.22. The stock has a market cap of $1.88 billion, a P/E ratio of -29.44 and a beta of -1.10. Wave Life Sciences Ltd. has a twelve month low of $3.50 and a twelve month high of $15.92.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.09). The business had revenue of $19.69 million for the quarter, compared to analysts’ expectations of $24.80 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 1,395.99%. During the same quarter in the previous year, the firm earned ($0.20) EPS. On average, equities research analysts expect that Wave Life Sciences Ltd. will post -1.02 earnings per share for the current fiscal year.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.